| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies [B. H. J., P. L., R. K. P.] and Division of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research [F. V.], Food and Drug Administration, Bethesda, MD 20892-4555; Carolina Neurosurgery and Spine, Charlotte, North Carolina 28207 [A. A.]; and Department of Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195 [R. A. P.]
We have reported that human malignant glioma cell lines express high levels of plasma membrane interleukin-4 receptors (IL-4R). We have also reported that biopsy/surgical samples or primary explant cell cultures from brain tumors express mRNA and protein for the IL-4R
chain, a primary IL-4-binding protein. However, whether IL-4R are expressed in brain tumors in situ has not been resolved. In addition, expression of IL-4R on the cell surface of various normal brain tissues is not known. We examined the expression of IL-4R by using a monoclonal antibody to the IL-4R
chain (also known as IL-4R ß) in surgical/biopsy samples of brain tumor tissues by immunohistochemistry. Our data indicate that 15 of 18 glioblastoma multiforme (GBMs) tumors obtained from two different institutions and 12 other brain tumor samples are moderately to intensely positive for IL-4R
. In contrast, although IL-4R
mRNA was expressed, no IL-4R protein was detectable in two adult and one pediatric brain tissue specimens. In addition, a commercially available human neural tissue grid containing fixed tissues from various areas of brain showed no positive staining for the IL-4R
chain. IL-4R
expression was also demonstrated on astrocytoma grades I, II, and III. Because IL-4 cytotoxin comprised of a circularly permutated IL-4 and a mutated form of Pseudomonas exotoxin [IL4(3837)-PE38KDEL] is cytotoxic to IL-4R-expressing cells, we tested whether primary GBM explant cell cultures are sensitive to IL-4 cytotoxin. Our data indicate that 13 of 15 GBM cell cultures were 2574 times more sensitive to IL-4 cytotoxin compared with normal human astrocytes or the NT2 neuronal cell line. These observations indicate that human brain tumors in situ overexpress IL-4R compared with normal brain tissues, thus confirming our previous conclusions that IL-4R in brain tumors may serve as an attractive target for anticancer therapy.
This article has been cited by other articles:
![]() |
Y. Mardor, D. Last, D. Daniels, R. Shneor, S. E. Maier, D. Nass, and Z. Ram Convection-Enhanced Drug Delivery of Interleukin-4 Pseudomonas Exotoxin (PRX321): Increased Distribution and Magnetic Resonance Monitoring J. Pharmacol. Exp. Ther., August 1, 2009; 330(2): 520 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kioi, S. Takahashi, M. Kawakami, K. Kawakami, R. J. Kreitman, and R. K. Puri Expression and Targeting of Interleukin-4 Receptor for Primary and Advanced Ovarian Cancer Therapy Cancer Res., September 15, 2005; 65(18): 8388 - 8396. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. I. Samoylova, V. A. Petrenko, N. E. Morrison, L. P. Globa, H. J. Baker, and N. R. Cox Phage probes for malignant glial cells Mol. Cancer Ther., November 1, 2003; 2(11): 1129 - 1137. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Liu, S. B. Tatter, M. C. Willingham, M. Yang, J. J. Hu, and A. E. Frankel Growth Factor Receptor Expression Varies among High-Grade Gliomas and Normal Brain: Epidermal Growth Factor Receptor Has Excellent Properties for Interstitial Fusion Protein Therapy Mol. Cancer Ther., August 1, 2003; 2(8): 783 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kawakami, M. Kawakami, S. R. Husain, and R. K. Puri Effect of Interleukin (IL)-4 Cytotoxin on Breast Tumor Growth after in Vivo Gene Transfer of IL-4 Receptor {alpha} Chain Clin. Cancer Res., May 1, 2003; 9(5): 1826 - 1836. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kawakami, M. Kawakami, P. Leland, and R. K. Puri Internalization Property of Interleukin-4 Receptor {alpha} Chain Increases Cytotoxic Effect of Interleukin-4 Receptor-targeted Cytotoxin in Cancer Cells Clin. Cancer Res., January 1, 2002; 8(1): 258 - 266. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |